Guanethidine

Summary

Guanethidine (CHEMBL765) is an approved small-molecule antihypertensive agent (ATC S01EX01); indicated across 2 conditions including hypertensive disorder and glaucoma.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: S01EX01 (+1 more)
• Indications: 2 conditions
• Chemistry: 198.31 Da · C10H22N4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL765
Name	Guanethidine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	3518
ChEBI	CHEBI:5557
ATC	S01EX01, C02CC02
Molecular formula	C10H22N4
Molecular weight	198.31
InChIKey	ACGDKVXYNVEAGU-UHFFFAOYSA-N

SMILES: C1CCCN(CCC1)CCN=C(N)N

IUPAC name: 2-[2-(azocan-1-yl)ethyl]guanidine

ChEBI definition: A member of the class of guanidines in which one of the hydrogens of the amino group has been replaced by a 2-azocan-1-ylethyl group.

Pharmacological roles (ChEBI): antihypertensive agent, adrenergic antagonist, sympatholytic agent.

Also known as: Esimil, Guanethidine, Guanetidina, SID11112157, guanethidine, GUANETHIDINE, GUANETHIDINE MONOSULFATE

Parent form; salt/anhydrous children: CHEMBL1345, CHEMBL2051958, CHEMBL3560112

Patent coverage: 4,538 distinct patent families (16,700 SureChEMBL compound mentions), from 2 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Prelamin-A/C.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
LMNA	5.85	Potency	1412	nM	CHEMBL_ACT_3640683

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
hypertensive disorder	4	MONDO:0005044	EFO:0000537
glaucoma	4	MONDO:0005041	MONDO:0005041

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).